Investor Relations

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel medicines for the management of central nervous system (CNS) disorders. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate. Our pipeline includes two late-stage product candidates, AXS-02 and AXS-05, which we are developing for multiple indications.

NASDAQ AXSM (Common Stock) $4.80 - 0.08 (1.64%)
Stock chart for: AXSM.O.  Currently trading at $4.80 with a 52 week high of $9.11 and a 52 week low of $3.53.
Data provided by Nasdaq. Minimum 15 minutes delayed.

Axsome Therapeutics Reports Second Quarter 2017 Financial Results

August 9, 2017NEW YORK, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the quarter ended June 30, 2017. “We continued our forward momentum in the second quarter with the expansion of our clinical programs as well as our team,” said Herriot Tabuteau, M.D., Chief Executive Officer of Axsome. “Our clinical pipelin... 

Axsome Therapeutics Announces AXS-06 (MoSEIC™ Meloxicam and Esomeprazole) Meets Primary Endpoint in Phase 1 Clinical Trial

July 25, 2017AXS-06 is an oral, rapidly-absorbed, once-daily, non-opioid, COX-2 preferential pain therapeutic with a gastroprotectant Primary endpoint met with 9 times faster time to maximum plasma concentration (Tmax) of meloxicam versus Mobic® (p<0.0001) Therapeutic plasma levels of meloxicam achieved within 15 minutes of oral dosing of AXS-06 Gastroprotective concentrations of esomeprazole achieved  Phase 3-ready based on FDA Pre-IND guidance AXS-06 utilizes Axsome’s MoSEIC™ delivery technology... 

Axsome Therapeutics Initiates Phase 2/3 Trial of AXS-05 for Alzheimer’s Disease Agitation

July 17, 2017First patient enrolled in the ADVANCE-1 study Agitation reported in nearly 50% of patients with Alzheimer’s disease FDA Fast Track designation previously received for AXS-05 for Alzheimer’s disease agitation Second indication for AXS-05 in late-stage clinical trials NEW YORK, July 17, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolle...